Peri-Operative Medicine John Cohn

Total Page:16

File Type:pdf, Size:1020Kb

Peri-Operative Medicine John Cohn Perioperative Medicine Steven L. Cohn (Editor) Perioperative Medicine Editor Steven L. Cohn Director – Medical Consultation Service Kings County Hospital Center Clinical Professor of Medicine SUNY Downstate Brooklyn, NY ISBN 978-0-85729-497-5 e-ISBN 978-0-85729-498-2 DOI 10.1007/978-0-85729-498-2 Springer London Dordrecht Heidelberg New York British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Control Number: 2011931531 © Springer-Verlag London Limited 2011 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permit- ted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licenses issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Preface Preoperative risk assessment and perioperative management are important aspects of clinical practice in internal medicine. Whereas surgeons and anesthesiologists spend most of their time caring for patients in the perioperative period, many primary-care physicians and hospitalists may feel inadequately trained or uncomfortable in this setting. The goal of this book is to provide a streamlined approach to the medical aspects of perioperative care, limiting content to make it an easily readable and clinically useful guide. It is intended for use by hospitalists, general internists and specialists, anesthesiolo- gists, surgeons, and residents in training who are involved in the care of patients before and after surgery. The book is divided into four parts. The first part addresses general aspects of periop- erative care, preoperative testing, medication management, and prophylaxis (surgical site infection, venous thromboembolism, endocarditis). The second part highlights aspects specific to various types of surgery, including patient- and surgery-specific risk factors and procedural complications. The third part reviews preoperative evaluation and periopera- tive management of coexisting medical conditions that affect surgical risk. The last part covers evaluation and management of some of the more frequently encountered postopera- tive complications. Because medicine is a constantly changing field, new information may affect some of the recommendations in this book. The information contained in this book is based on what the authors felt was the best available evidence at the time. Additionally, errors, inac- curacies, and omissions may inadvertently occur despite the care that has been taken to avoid them. The reader is advised to use sound clinical judgment and to confirm all doses of medications before prescribing them. I hope that you will find this information useful in your clinical practice and hope that it will lead to improved perioperative patient care. Steven L. Cohn, M.D., FACP v Acknowledgment I would like to thank the authors, most of whom are practicing internists, hospitalists, or anesthesiologists and members of the Society of General Internal Medicine (SGIM) Perioperative Medical Consultation Interest Group (www.sgim.org) or the Society for Perioperative Assessment and Quality Improvement (www.spaqi.org), who have contrib- uted chapters for this book. I would also like to acknowledge my wife, Deborah, children, Alison and Jeffrey, and mother, Lynn, for their love, encouragement, and support in general and specifically during this project. Steven L. Cohn, M.D., FACP vii Contents Part I Preoperative Evaluation 1 Role of the Medical Consultant ........................................................................... 3 Steven L. Cohn 2 Preoperative Testing ............................................................................................. 13 L. Reuven Pasternak 3 Perioperative Medication Management .............................................................. 23 Steven L. Cohn 4 Perioperative Management of Anticoagulation ................................................. 45 Scott Kaatz and David G. Paje 5 Venous Thromboembolism Prophylaxis ............................................................. 55 Steven L. Cohn 6 Prevention of Infective Endocarditis (Bacterial Endocarditis Prophylaxis) .................................................................. 67 Steven L. Cohn 7 Surgical Site Infection Prophylaxis ..................................................................... 73 Amish Ajit Dangodara 8 Anesthesiology for the Nonanesthesiologist ........................................................ 81 Vivek K. Moitra and Rebecca S. Twersky Part II Surgery-Specific Risks 9 Abdominal Surgery ............................................................................................... 99 Brian Woods 10 Thoracic Surgery .................................................................................................. 107 Vivek K. Moitra ix x Contents 11 Vascular Surgery ................................................................................................... 115 Visala S. Muluk 12 Orthopedic Surgery .............................................................................................. 123 Ronald MacKenzie and Edwin P. Su 13 Neurosurgery ......................................................................................................... 131 Victor Duval 14 Gynecologic Surgery ............................................................................................. 137 Bruce E. Johnson 15 Urologic Surgery ................................................................................................... 145 Bruce E. Johnson 16 Bariatric Surgery .................................................................................................. 151 Brian Harte 17 Ophthalmic Surgery ............................................................................................. 161 Deborah C. Richman 18 Otolaryngologic Procedures ................................................................................. 169 Paul J. Primeaux 19 Electroconvulsive Therapy ................................................................................... 179 Howard S. Smith Part III Preoperative Evaluation and Management of Co-existing Medical Diseases 20 Cardiac Disease ..................................................................................................... 189 Steven L. Cohn 21 Pulmonary Disease ................................................................................................ 211 Steven L. Cohn 22 Endocrine Disease ................................................................................................. 227 Amish Ajit Dangodara and Visala S. Muluk 23 Hematologic Disease ............................................................................................. 261 Shuwei Gao and Sunil K. Sahai 24 Cancer .................................................................................................................. 281 Sunil K. Sahai and Ellen F. Manzullo Contents xi 25 HIV ........................................................................................................................ 295 Richard B. Brooks 26 Chronic Kidney Disease ....................................................................................... 303 Mihaela S. Stefan and Adam C. Schaffer 27 GI Disease .............................................................................................................. 315 Nomi L. Traub and Richard B. Brooks 28 Rheumatic Disease ................................................................................................ 329 Brian F. Mandell 29 Neurological Disease ............................................................................................. 343 Lane K. Jacobs and Benjamin L. Sapers 30 Psychiatric Conditions .......................................................................................... 361 Joleen Elizabeth Fixley and Meghan Collen Tadel 31 Substance Abuse ................................................................................................... 381 Nadene C. Fair and Howard S. Smith 32 The Pregnant Surgical Patient ............................................................................. 395 Beth G. Lewis and Michael P. Carson Part IV Postoperative Complications 33 Postoperative Fever .............................................................................................. 411 Barbara A. Cooper and Nadene C. Fair 34 Postoperative Hypertension/Hypotension .......................................................... 421 Steven L. Cohn and Brian Harte 35 Postoperative Arrhythmias .................................................................................. 431 Barbara Slawski and Kurt Pfeifer 36
Loading...
Loading...
Loading...
Loading...
Loading...

552 pages remaining, click to load more.

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Modifications of Nucleic Acid Precursors That Inhibit Plant Virus Multiplication
    Molecular Plant Pathology Modifications of Nucleic Acid Precursors That Inhibit Plant Virus Multiplication William 0. Dawson and Carol Boyd Department of Plant Pathology, University of California, Riverside 92521. This work was supported in part by U.S. Department of Agriculture Grant 84-CTC-1-1402. Accepted for publication 4 April 1986. ABSTRACT Dawson, W. 0., and Boyd, C. 1987. Modifications of nucleic acid precursors that inhibit plant virus multiplication. Phytopathology 77:477-480. The relationship between chemical modifications of normal nucleic acid highest proportion of antiviral activity were modification of the sugar base or nucleoside precursors and ability to inhibit multiplication of moiety (five of 13 chemicals were inhibitory) and addition of abnormal side tobacco mosaic virus or cowpea chlorotic mottle virus in disks from groups (three of seven chemicals were inhibitory). Eight new inhibitors of mechanically inoculated leaves was tested with 131 analogues. Chemicals virus multiplication were identified: 6-aminocytosine; 6-ethyl- tested were selected from 10 general classes of modifications to determine mercaptopurine; isopentenyladenosine; 2-thiopyrimidine; 2,4-dithio- the types of modifications of normal nucleic acid precursors that have pyrimidine; melamine; 5'-iodo-5'-deoxyadenosine; and 5'- greater probabilities of inhibiting virus multiplication. No inhibitory methyl-5'-deoxythioadenosine. chemicals were found in several classes. Classes of modifications with the Additionalkey words: antivirals, chemotherapy, control, virus diseases. The ability to control virus diseases of plants with chemicals different taxonomic groups, tobacco mosaic virus (TMV) in would be a valuable addition to existing control strategies. This tobacco and cowpea chlorotic mottle virus (CCMV) in cowpea. could be particularly useful in in vitro culture procedures to Chemicals were chosen to be tested based on two different criteria.
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • A Framework for Assurance of Medication Safety Using Machine Learning
    A Framework for Assurance of Medication Safety using Machine Learning Yan Jia1 Tom Lawton2 John McDermid1 Eric Rojas3 Ibrahim Habli1 Abstract— Medication errors continue to be the leading cause of avoidable patient harm in hospitals. This paper sets out a framework to assure medication safety that combines machine learning and safety engineering methods. It uses safety analysis to proactively identify potential causes of medication error, based on expert opinion. As healthcare is now data rich, it is possible to augment safety analysis with machine learning to discover actual causes of medication error from the data, and to identify where they deviate from what was predicted in the safety analysis. Combining these two views has the potential to enable the risk of medication errors to be managed proactively and dynamically. We apply the framework to a case study involving thoracic surgery, e.g. oesophagectomy, where errors in giving beta-blockers can be critical to control atrial fibrillation. This case study combines a HAZOP-based safety analysis method known as SHARD with Bayesian network structure learning and process mining to produce the analysis results, showing the potential of the framework for ensuring patient safety, and for transforming the way that safety is managed in complex healthcare environments. Keywords—medication safety, machine learning, proactive safety management 1. INTRODUCTION Safety analysis is both predictive and reactive. It aims to identify hazards, hazard causes and mitigations, and associated risks before a system is deployed. The system is then monitored during its deployment to manage risks. When systems are used in highly controlled environments, built using components with a long service history, these predictions can be accurate.
    [Show full text]
  • Psychiatric Medications in Behavioral Healthcarev5
    Copyright © The University of South Florida, 2012 Psychiatric Medications in Behavioral Healthcare An Important Notice None of the pages in this tutorial are meant to be a replacement for professional help. The science of medicine is constantly changing, and these changes alter treatment and drug therapies as a result of what is learned through research and clinical experience. The author has relied on resources believed to be reliable at the time material was developed. However, there is always the possibility of human error or changes in medical science and neither the authors nor the University of South Florida can guarantee that all the information in this program is in every respect accurate or complete and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Each person that reads this program is encouraged to confirm the information with other sources and understand that it not be interpreted as medical or professional advice. All medical information needs to be carefully reviewed with a health care provider. Course Objectives At the completion of this program participants should be able to: • Identify at 5 categories of medications used to treat the symptoms of psychiatric disorders, the therapeutic effects of medications in each category, and the side effects associated with medications in each category. • Identify at least 5 medications and the benefits of those medications as compared to the medications. • Identify at least 5 reasons that a person may stop taking medications or not take medications as prescribed. • Demonstrate your learned understanding of psychiatric medications by passing the combined post‐ tests.
    [Show full text]
  • The Psychoactive Effects of Psychiatric Medication: the Elephant in the Room
    Journal of Psychoactive Drugs, 45 (5), 409–415, 2013 Published with license by Taylor & Francis ISSN: 0279-1072 print / 2159-9777 online DOI: 10.1080/02791072.2013.845328 The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room Joanna Moncrieff, M.B.B.S.a; David Cohenb & Sally Porterc Abstract —The psychoactive effects of psychiatric medications have been obscured by the presump- tion that these medications have disease-specific actions. Exploiting the parallels with the psychoactive effects and uses of recreational substances helps to highlight the psychoactive properties of psychi- atric medications and their impact on people with psychiatric problems. We discuss how psychoactive effects produced by different drugs prescribed in psychiatric practice might modify various disturb- ing and distressing symptoms, and we also consider the costs of these psychoactive effects on the mental well-being of the user. We examine the issue of dependence, and the need for support for peo- ple wishing to withdraw from psychiatric medication. We consider how the reality of psychoactive effects undermines the idea that psychiatric drugs work by targeting underlying disease processes, since psychoactive effects can themselves directly modify mental and behavioral symptoms and thus affect the results of placebo-controlled trials. These effects and their impact also raise questions about the validity and importance of modern diagnosis systems. Extensive research is needed to clarify the range of acute and longer-term mental, behavioral, and physical effects induced by psychiatric drugs, both during and after consumption and withdrawal, to enable users and prescribers to exploit their psychoactive effects judiciously in a safe and more informed manner.
    [Show full text]
  • Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues
    Published OnlineFirst September 8, 2009; DOI: 10.1158/0008-5472.CAN-09-1927 Experimental Therapeutics, Molecular Targets, and Chemical Biology Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues Dong Wu,1 Yang Li,1 Gaojie Song,1 Chongyun Cheng,1 Rongguang Zhang,2 Andrzej Joachimiak,2 NeilShaw, 1 and Zhi-Jie Liu1 1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China and 2Structural Biology Center, Argonne National Laboratory, Argonne, Illinois Abstract of the one-carbon metabolic network, dihydrofolate reductase, 5,10-Methenyltetrahydrofolate synthetase (MTHFS) regulates which catalyzes the conversion of dihydrofolate to tetrahydrofolate. the flow of carbon through the one-carbon metabolic network, Similarly, colorectal and pancreatic cancers are routinely treated by which supplies essential components for the growth and administration of the pyrimidine analogue 5-fluorouracil (5-FU), proliferation of cells. Inhibition of MTHFS in human MCF-7 which inhibits thymidylate synthase (TS; ref. 6). TS converts breast cancer cells has been shown to arrest the growth of deoxyuridylate to deoxythymidylate using a carbon donated by cells. Absence of the three-dimensional structure of human 5,10-methylenetetrahydrofolate (Fig. 1). This conversion is essential MTHFS (hMTHFS) has hampered the rational design and for DNA synthesis (7). To increase the clinical efficiency of the optimization of drug candidates. Here, we report the treatment, 5-formyltetrahydrofolate is often coadministered along structures of native hMTHFS, a binary complex of hMTHFS with 5-FU. The beneficial effect of administering 5-formyltetrahy- with ADP, hMTHFS bound with the N5-iminium phosphate drofolate during the therapy with 5-FU is a consequence of the reaction intermediate, and an enzyme-product complex of 5,10-methenyltetrahydrofolate synthetase (MTHFS)–catalyzed hMTHFS.
    [Show full text]
  • Bendamustine and Cytosine Arabinoside: a Highly Synergistic Combination Visco C*, Carli G and Rodeghiero F Further DNA Synthesis [24]
    Open Access Austin Journal of Cancer and Clinical Research Editorial Bendamustine and Cytosine Arabinoside: A Highly Synergistic Combination Visco C*, Carli G and Rodeghiero F further DNA synthesis [24]. The synergistic effect of bendamustine Department of Cell Therapy and Hematology, San Bortolo and cytarabine could be related to the individual mechanism of Hospital, Italy action of the two drugs, whose serial administration would avoid *Corresponding author: Carlo Visco, Department of the saturation of the common pathways. Cells escaping the cell cycle Cell Therapy and Hematology, San Bortolo Hospital, Via arrest induced by bendamustine and trying to repair their damage Rodolfi 37, 36100 Vicenza, Italy, Tel: +39 0444 753626; would be prone to incorporate the metabolite ara-CTP into DNA, Fax: +39 0444 920708; Email: carlovisco@hotmail.com as reported by Staib [19] in acute myeloid leukemia cells. Indeed, the Received: January 07, 2015; Accepted: March 16, sequential treatment with bendamustine followed by cytarabine was 2015; Published: April 03, 2015 proven to be more effective than simultaneous addition of the two drugs (Figure 2) [21-23]. The S phase of the cell cycle is a crucial step Editorial of replication in mantle cell lymphoma (MCL) cells, where cyclin D1 Bendamustine is a bifunctional compound that has shown clinical overexpression deregulates the cell cycle at the G1/S phase transition, activity against various human cancers including non-Hodgkin’s and and is likely the engine continuously pushing cells towards S-phase Hodgkin’s lymphoma [1,2], chronic lymphocytic leukemia (CLL) [3], (Figure 3). Indeed, both drugs are known to be particularly active in multiple myeloma [4,5], breast cancer [6], and small-cell lung cancer patients with MCL.
    [Show full text]
  • Annual Report 2016
    Annexes to the annual report of the European Medicines Agency 2016 Annex 1 – Members of the Management Board ............................................................... 2 Annex 2 - Members of the Committee for Medicinal Products for Human Use ...................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ........................ 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ................. 8 Annex 5 – Members of the Committee on Orphan Medicinal Products .............................. 10 Annex 6 – Members of the Committee on Herbal Medicinal Products ................................ 12 Annex 7 – Committee for Advanced Therapies .............................................................. 14 Annex 8 – Members of the Paediatric Committee .......................................................... 16 Annex 9 – Working parties and working groups ............................................................ 18 Annex 10 – CHMP opinions: initial evaluations and extensions of therapeutic indication ..... 24 Annex 10a – Guidelines and concept papers adopted by CHMP in 2016 ............................ 25 Annex 11 – CVMP opinions in 2016 on medicinal products for veterinary use .................... 33 Annex 11a – 2016 CVMP opinions on extensions of indication for medicinal products for veterinary use .......................................................................................................... 39 Annex 11b – Guidelines and concept papers adopted by CVMP in 2016 ...........................
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – November 2015 Foreword Biopharma owes much of the past few years’ bull run to advances in cancer – specifically to immuno-oncology approaches that harness the natural power of the immune system to combat disease. The charge has been led by antibodies against CTLA4 and PD-1, which have seen the launches of Yervoy, Opdivo and Keytruda, initially for melanoma but with additional indications now getting under way. What does the industry do for an encore? There are several late-stage antibodies that work in identical or similar ways – tremelimumab, atezolizumab and durvalumab – and slightly further away stands an amazing array of novel immuno-oncology approaches, which target novel antigens or novel immune system checkpoints. But most experts are now looking to combinations to build on the success of the first few immuno-oncology drugs to hit the market. This is a vital theme because, in investment terms, biopharma looks like it might at last have overheated, and as such it is desperate for another lift. The coming 18 months could provide several. The key lies in the first clinical evidence from early trials of anti-PD-1 and anti-PD-L1 antibodies combined with novel immune system agents, as well as in combination with a barrage of old and new small-molecule and antibody drugs, chemotherapies, cancer vaccines and gene therapies. Combining numerous new and old approaches with anti-PD-1/PD-L1 agents is logical given that the latter already look like they are becoming standard treatment in certain populations within certain tumour types.
    [Show full text]
  • Drug Therapy of Cancer Curt Peterson
    Drug therapy of cancer Curt Peterson To cite this version: Curt Peterson. Drug therapy of cancer. European Journal of Clinical Pharmacology, Springer Verlag, 2011, 67 (5), pp.437-447. 10.1007/s00228-011-1011-x. hal-00671936 HAL Id: hal-00671936 https://hal.archives-ouvertes.fr/hal-00671936 Submitted on 20 Feb 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 110130 Drug therapy of cancer Curt Peterson Professor, MD, PhD Departments of Clinical Pharmacology and Oncology University hospital SE-581 85 Linköping Sweden curt.peterson@liu.se, tel: +46101031090, fax: +4613104195 2 Abstract Cancer chemotherapy was introduced at the same time as antibacterial chemotherapy but has not at all been such a success. However, there is a growing optimism in oncology today due to the introduction of several more or less target specific drugs as complement to the conventional cytotoxic drugs introduced half a century ago. The success in the treatment of chronic myelogenous leukemia by imatinib, inhibiting the bcr-abl activated tyrosine kinase thereby interrupting the signal transduction pathways that lead to leukemic transformation. with impressive survival benefit has paved the way for this new optimism.
    [Show full text]
  • VOL. XXVII, No. 3-4, 2011 20112011 Heart Diseases in Essential Thrombocythemia Review
    VOL. XXVII, No. 3-4, 2011 20112011 Heart diseases in essential Thrombocythemia review Mihaela Rugină1 , L. Predescu 1, V.Molfea 1, I. M. Coman 1,2,Ş . Bubenek- Turconi 1,2 1. “C.C.Iliescu" Emergency Institute for Cardiovascular Diseases 2. “Carol Davila” University of Medicine and Pharmacy, Bucharestepartment of the Emergency Universitary Hospital –Bucharest Contact address: Dr. Mihaela Rugină,Ş , “C.C.Iliescu" Emergency Institute for Cardiovascular Diseases os. Fundeni 258, Sector 2, 022328, Bucharest • E-mail: rugina.mihaela@gmail.com Abstract Essential thrombocythemia (ET) is a myeloproliferative disorder that raises questions about the characteristics of the disease treatment. ET evolution is grafted to a predisposition to bleeding and thrombotic events and microvascular events. Thrombotic events often affects medium-sized and large arteries including cerebral arteries, coronary and peripheral, but can also affect the veins causing recurrent venous thrombosis of the legs with thromboembolic complications. The most common cardiac complications occurred in the ET are the acute coronary syndromes or coronary thrombosis, and in some cases has been incriminated and coronary spasm. Possible cardiac valvular damage that can occur in ET (thickening, calcification, valvular regurgitation) and the possibility of associating with pulmonary arterial hypertension who aren't associated to a pulmonary embolism are reported in the literature but with an extremely rare incidence. Key words: essential thrombocythemia, acute coronary syndroms, thrombosis
    [Show full text]